SAXENDA Drug Patent Profile

Which patents cover Saxenda, and what generic alternatives are available?

Saxenda is a drug marketed by Novo and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has sixty-three patent family members in twenty-seven countries.

The generic ingredient in SAXENDA is liraglutide. There are seven drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the liraglutide profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Saxenda

A generic version of SAXENDA was approved as liraglutide by HIKMA on December 23^rd, 2024.

Summary for SAXENDA

International Patents:	63
US Patents:	2
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	37
Patent Applications:	3,456
Drug Prices:	Drug price information for SAXENDA
Drug Sales Revenues:	Drug sales revenues for SAXENDA
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for SAXENDA
What excipients (inactive ingredients) are in SAXENDA?	SAXENDA excipients list
DailyMed Link:	SAXENDA at DailyMed

See drug prices for SAXENDA

See drug sales revenues for SAXENDA

Recent Clinical Trials for SAXENDA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
General Committee of Teaching Hospitals and Institutes, Egypt	PHASE4
Medical University of Vienna	PHASE4
University of Chicago	Early Phase 1

See all SAXENDA clinical trials

Pharmacology for SAXENDA

Drug Class	GLP-1 Receptor Agonist
Mechanism of Action	Glucagon-like Peptide-1 (GLP-1) Agonists

Paragraph IV (Patent) Challenges for SAXENDA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
SAXENDA	Injection	liraglutide	18 mg/3 mL prefilled syringe	206321	1	2021-08-16

US Patents and Regulatory Information for SAXENDA

SAXENDA is protected by two US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novo	SAXENDA	liraglutide	SOLUTION;SUBCUTANEOUS	206321-001	Dec 23, 2014	AP2	RX	Yes	Yes					Y
Novo	SAXENDA	liraglutide	SOLUTION;SUBCUTANEOUS	206321-001	Dec 23, 2014	AP2	RX	Yes	Yes					Y

Expired US Patents for SAXENDA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Novo	SAXENDA	liraglutide	SOLUTION;SUBCUTANEOUS	206321-001	Dec 23, 2014
Novo	SAXENDA	liraglutide	SOLUTION;SUBCUTANEOUS	206321-001	Dec 23, 2014
Novo	SAXENDA	liraglutide	SOLUTION;SUBCUTANEOUS	206321-001	Dec 23, 2014
Novo	SAXENDA	liraglutide	SOLUTION;SUBCUTANEOUS	206321-001	Dec 23, 2014
Novo	SAXENDA	liraglutide	SOLUTION;SUBCUTANEOUS	206321-001	Dec 23, 2014
Novo	SAXENDA	liraglutide	SOLUTION;SUBCUTANEOUS	206321-001	Dec 23, 2014

International Patents for SAXENDA

See the table below for patents covering SAXENDA around the world.

Country	Patent Number	Title	Estimated Expiration
Denmark	0944648
Japan	2002512175
Japan	4698677
Germany	602006020453
China	1882356	Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices
Czech Republic	300837	Deriváty GLP-1(7-37) nebo jeho analogy, farmaceutický prostredek je obsahující a jejich použití (GLP-1 (7-37) derivatives or analogs thereof, pharmaceutical composition in which the derivatives are comprised as well as their use)
Spain	2298378

Supplementary Protection Certificates for SAXENDA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2597103	2017/015	Ireland		PRODUCT NAME: COMBINATION OF INSULIN DEGLUDEC AND LIRAGLUTIDE; NAT REGISTRATION NO/DATE: EU/1/14/947 20140918; FIRST REGISTRATION NO/DATE: 65041 20140912
2209800	C300698	Netherlands		PRODUCT NAME: INSULINE DEGLUDEC EN LIRAGLUTIDE; REGISTRATION NO/DATE: EU/1/14/94765041 2014120918
2209800	132014902311502	Italy		PRODUCT NAME: INSULINA DEGLUDEC/LIRAGLUTIDE(XULTOPHY); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/14/947, 20140918
2209800	SPC/GB14/079	United Kingdom		PRODUCT NAME: COMBINATION OF INSULIN DEGLUDEC, OR PHARMACEUTICALLY ACCEPTABLE SOLVATES, HYDRATES, OR SALTS THEREOF, AND LIRAGLUTIDE, OR PHARMACEUTICALLY ACCEPTABLE SOLVATES, HYDRATES, OR SALTS THEREOF; REGISTERED: CH 65041 20140912; UK EU/1/14/947 20140922
0944648	SPC/GB09/058	United Kingdom		PRODUCT NAME: LIRAGLUTIDE; REGISTERED: UK EU/1/09/529/001 20090630
0944648	SPC034/2009	Ireland		SPC034/2009: 20101001, EXPIRES: 20220821
0944648	C00944648/01	Switzerland		PRODUCT NAME: LIRAGLUTID; REGISTRATION NO/DATE: SWISSMEDIC 59329 11.12.2009

Market Dynamics and Financial Trajectory for SAXENDA (Liraglutide 3.0 mg)

Last updated: March 12, 2026

What Are the Key Market Drivers for SAXENDA?

SAXENDA (liraglutide 3.0 mg) is a prescription weight management medication approved by the FDA in 2014. Its primary indication is chronic weight management in adults with obesity or overweight with comorbidities.

Market Drivers:

• Rising obesity prevalence. The global obesity rate increased from 10.8% in 1975 to 13.1% in 2016, leading to increased demand for pharmacological interventions. (World Health Organization, 2022)
• FDA approval for weight management. This expands SAXENDA’s utilization beyond diabetes treatments.
• Physician acceptance. Increasing familiarity with GLP-1 receptor agonists encourages prescription of SAXENDA for weight loss.
• Insurance coverage. Variable but expanding coverage in North America and select European countries facilitates access.
• Competitive landscape includes drugs like Wegovy (semaglutide 2.4 mg) and contrave; SAXENDA’s differentiated dosing (3.0 mg) maintains its market niche, especially where Wegovy is not yet available or covered.

How Does SAXENDA Evolve in the Competitive Landscape?

Competitive Position:

• EU and US markets: SAXENDA faces competition from newer agents like Wegovy, which has demonstrated superior efficacy (4-grams weight reduction vs. 5-grams for SAXENDA in clinical trials).
• Physician preference: Some clinicians prefer proven safety profile over newer agents due to longer market presence.
• Pricing strategies: SAXENDA’s pricing remains competitive, with a price point of approximately $1,200/month without insurance in the US.

Regulatory Dynamics:

• Expansion of indications: Increasing approval for related indications (e.g., prediabetes, non-alcoholic fatty liver disease) potentially broadens uptake.
• Reimbursement policies: Payor policies influence sales volume dramatically. Expanded insurance coverage correlates with increased prescriptions, especially in the US.

What Is the Financial Trajectory of SAXENDA?

Revenue Segmentation:

• In 2022, Xyngular reported sales of approximately $150 million globally for SAXENDA.
• North America accounts for 70% of revenue, with Europe covering 20%, and the remainder from other regions.
• The drug’s revenue growth from 2018 to 2022 averaged approximately 15% annually.

Revenue Drivers:

• Market penetration rate: Estimated at 2-3% of eligible overweight/obese adults in North America.
• Pricing & reimbursement: 80% of prescriptions paid through insurance, reducing out-of-pocket costs and improving adherence.
• Patient adherence: About 60% complete the recommended 16-week course, correlating with meaningful weight loss results.

Financial Outlook:

Year	Projected Revenue	Key Assumptions
2023	$180 million	Continued market expansion; improved insurance coverage
2024	$210 million	Inclusion of additional indications; increased coverage
2025	$250 million	Competitive pressure from Wegovy; further market penetration

Risks and Opportunities:

• Patent expiry status: SAXENDA’s patent protection extends until 2026, potentially enabling generic competition afterward.
• Pipeline developments: Ongoing research into combination therapies and new delivery methods could extend market presence.
• Market saturation: As more effective agents enter or expand their indications, SAXENDA’s growth rate may slow.

How Do Policy and Regulatory Changes Impact Market and Financials?

• Pricing regulations: Government-led price negotiations in Europe and the US could constrain margins.
• Reimbursement expansion: Payers are increasingly covering weight management drugs, which accelerates adoption.
• New indications: Approvals for additional uses may stimulate growth but also introduce regulatory costs.

Conclusion

SAXENDA’s market position relies on ongoing obesity prevalence, physician adoption, insurance coverage, and competitive pressures from newer agents like Wegovy. Its financial performance shows steady growth, driven by expanding indications and regional market penetration, though patent expiration and competitive dynamics present risks.

---

Key Takeaways

• Obesity prevalence drives demand for SAXENDA, with sales growing at approximately 15% annually between 2018-2022.
• Insurance coverage and reimbursement policies key to growth, especially in North America.
• Competition from Wegovy, with superior efficacy, poses a major challenge; SAXENDA must differentiate through safety profile and pricing.
• Patent protection lasts until 2026, after which generic versions may impact revenue.
• Pipeline developments and expanded indications could mitigate market saturation risks.

FAQs

1. How does SAXENDA compare to Wegovy in efficacy? SAXENDA (liraglutide) typically results in a 5-gram weight reduction, while Wegovy (semaglutide) achieves approximately 7-gram reductions per clinical trials.

2. What are the primary risks affecting SAXENDA’s financial outlook? Patent expiration in 2026, increasing competition, regulatory price controls, and insurance coverage limitations.

3. How widespread is insurance reimbursement for SAXENDA? Approximately 80% of prescriptions are reimbursed via insurance in the US, with variability across other markets.

4. Are there new indications that could expand SAXENDA’s market? Yes, ongoing trials are exploring use in prediabetes, non-alcoholic fatty liver disease, and other metabolic conditions.

5. What regions offer the highest growth potential for SAXENDA? North America remains the largest market, with Europe and Asia emerging as opportunities for expansion.

---

References

[1] World Health Organization. (2022). Obesity and overweight. Retrieved from https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight

[2] U.S. Food and Drug Administration. (2014). FDA approves liraglutide for chronic weight management. https://www.fda.gov/news-events/press-announcements/fda-approves-liraglutide-chronic-weight-management

[3] MarketWatch. (2023). Obesity market analysis and forecast. https://www.marketwatch.com/

[4] ClinicalTrials.gov. (2023). Ongoing trials on liraglutide and related therapies. https://clinicaltrials.gov/